Risk groups in febrile neutropenic patients.
| Risk Group . | Patient Characteristic . |
|---|---|
| High-risk | Severe (ANC < 100) and prolonged (> 14d) neutropenia. Hematological malignancy; allogeneic bone marrow/stem cell transplantation; significant medical co-morbidity or poor performance status; presentation with shock, complex infection (e.g. pneumonia, meningitis) |
| Intermediate (moderate) risk | Solid tumors → intensive chemotherapy → autologous hematopoetic stem cell transplantation. Moderate duration of neutropenia (7-14 days). Minimal medical comorbidity. Clinical/ hemodynamic stability. |
| Low-risk | Solid tumors → conventional chemotherapy. No comorbidity. Short duration of neutropenia (≤ 7 days). Clinical and hemodynamic stability. Unexplained fever (FUO) or simple infection (eg. UTI, simple cellulitis). |
| Risk Group . | Patient Characteristic . |
|---|---|
| High-risk | Severe (ANC < 100) and prolonged (> 14d) neutropenia. Hematological malignancy; allogeneic bone marrow/stem cell transplantation; significant medical co-morbidity or poor performance status; presentation with shock, complex infection (e.g. pneumonia, meningitis) |
| Intermediate (moderate) risk | Solid tumors → intensive chemotherapy → autologous hematopoetic stem cell transplantation. Moderate duration of neutropenia (7-14 days). Minimal medical comorbidity. Clinical/ hemodynamic stability. |
| Low-risk | Solid tumors → conventional chemotherapy. No comorbidity. Short duration of neutropenia (≤ 7 days). Clinical and hemodynamic stability. Unexplained fever (FUO) or simple infection (eg. UTI, simple cellulitis). |